|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Current assets: | ||||||||||||||||||||
| Cash and cash equivalents [note 5] | ||||||||||||||||||||
| Marketable securities [note 5] | ||||||||||||||||||||
| Short-term investments [note 6] | ||||||||||||||||||||
| Grant receivable [note 3] | ||||||||||||||||||||
| Prepaid expenses and other assets | ||||||||||||||||||||
| Nonrelated Party | ||||||||||||||||||||
| Related Parties | ||||||||||||||||||||
| Total prepaid expenses and other assets | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||
| Restricted cash and other assets [note 6 and note 7] | ||||||||||||||||||||
| Non-current assets: | ||||||||||||||||||||
| Other assets and restricted cash [note 5] | ||||||||||||||||||||
| Right-of-use assets [note 9] | ||||||||||||||||||||
| Other intangible assets | ||||||||||||||||||||
| License agreement [note 3 and note 4] | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Nonrelated Party | ||||||||||||||||||||
| Related Parties | ||||||||||||||||||||
| Total accounts payable | ||||||||||||||||||||
| Accrued liabilities other | ||||||||||||||||||||
| Nonrelated Party | ||||||||||||||||||||
| Related Parties | ||||||||||||||||||||
| Total accrued liabilities other | ||||||||||||||||||||
| Contingent consideration [note 5 and note 6] | ||||||||||||||||||||
| Accrued clinical liabilities | ||||||||||||||||||||
| Nonrelated Party | ||||||||||||||||||||
| Related Parties | ||||||||||||||||||||
| Total accrued clinical liabilities | ||||||||||||||||||||
| Accrued compensation | ||||||||||||||||||||
| Current contingent consideration [note 4 and note 5] | ||||||||||||||||||||
| Current portion of long-term obligations [note 9] | ||||||||||||||||||||
| Current portion of convertible debt [note 5 and note 6] | ||||||||||||||||||||
| Warrant liability | ||||||||||||||||||||
| Pre-funded warrant liability | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Non-current portion of convertible debt [note 5 and note 6] | ||||||||||||||||||||
| Non-current contingent consideration [note 4 and note 5] | ||||||||||||||||||||
| Long-term obligations [note 9] | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Stockholders' equity: | ||||||||||||||||||||
| Common stock, $0.001 par value, 150,000,000 shares authorized, 102,717,200 issued and outstanding at June 30, 2026 and 53,233,988 issued and outstanding at December 31, 2025 | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Accumulated other comprehensive income | ||||||||||||||||||||
| Total stockholders' equity | ||||||||||||||||||||
| Total liabilities and stockholders' equity |
Loading...
